Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. De Brito Léia (Vargem Grande Paulista, Brazil). Anti-inflammatory effects of Low Level Laser (LLL) in a murine model of asthma and its combination with the standard treatment. 1048

Member's Comments

No comment yet.

Related content which might interest you: Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Effect of low level light therapy (LLLT) on an experimental model of LPS-induced lung inflammation Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 Low power laser (LBP) therapy downregulates the allergic lung inflammation in experimental asthma model: Effect driven to signal transducer and activator of transduction 6 (STAT-6) Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 Effect of low dose theophylline as adjunct in treatment of COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Low-level laser therapy as a supplementary treatment in patients with moderate to severe persistent asthma Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Anti-inflammatory effect of low dose theophylline in school children with bronchial asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Effect of low level laser (LLL) and mesenchymal stem cells (htMSCs) therapies on cigarette-induced lung inflammation in mice Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003 The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Validation of FEV1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Inhaled formulation of angiotensin-(1-7) produces lung protective effects in a model of chronic asthma. Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Anti-inflammatory effects of aerobic exercise in a murine model of asthma: Role of leukotrienes pathway Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Low level laser in monotherapy or in combination with leukotriene receptor antagonists in the treatment of allergic lung inflammation Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014